ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 249 filers reported holding ACADIA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.57 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $14,976,145 | -50.9% | 718,625 | -43.6% | 0.00% | -50.0% |
Q2 2023 | $30,498,505 | +65.4% | 1,273,424 | +30.0% | 0.01% | +50.0% |
Q1 2023 | $18,438,669 | +16.9% | 979,738 | -1.1% | 0.00% | 0.0% |
Q4 2022 | $15,770,718 | -18.3% | 990,623 | -16.1% | 0.00% | 0.0% |
Q3 2022 | $19,311,000 | +29.6% | 1,180,398 | +11.6% | 0.00% | +33.3% |
Q2 2022 | $14,900,000 | -44.3% | 1,057,494 | -4.2% | 0.00% | -50.0% |
Q1 2022 | $26,748,000 | -3.0% | 1,104,377 | -6.6% | 0.01% | +20.0% |
Q4 2021 | $27,586,000 | +100.9% | 1,181,923 | +42.9% | 0.01% | +66.7% |
Q3 2021 | $13,734,000 | +0.3% | 826,846 | +47.3% | 0.00% | 0.0% |
Q2 2021 | $13,690,000 | -49.1% | 561,315 | -46.1% | 0.00% | -57.1% |
Q1 2021 | $26,890,000 | -50.4% | 1,042,249 | +2.7% | 0.01% | -50.0% |
Q4 2020 | $54,267,000 | +28.2% | 1,015,090 | -1.1% | 0.01% | +27.3% |
Q3 2020 | $42,321,000 | -23.7% | 1,025,967 | -10.4% | 0.01% | -31.2% |
Q2 2020 | $55,476,000 | -10.7% | 1,144,546 | -22.2% | 0.02% | -27.3% |
Q1 2020 | $62,149,000 | +15.9% | 1,470,977 | +17.3% | 0.02% | +57.1% |
Q4 2019 | $53,627,000 | +19.1% | 1,253,557 | +0.2% | 0.01% | +7.7% |
Q3 2019 | $45,037,000 | +3.4% | 1,251,376 | -23.2% | 0.01% | 0.0% |
Q2 2019 | $43,542,000 | -16.7% | 1,628,987 | -16.3% | 0.01% | -18.8% |
Q1 2019 | $52,246,000 | +33.1% | 1,945,845 | -19.8% | 0.02% | +33.3% |
Q4 2018 | $39,250,000 | +39.7% | 2,427,312 | +79.4% | 0.01% | +71.4% |
Q3 2018 | $28,095,000 | +121.4% | 1,353,307 | +62.9% | 0.01% | +133.3% |
Q2 2018 | $12,689,000 | -56.0% | 830,983 | -35.2% | 0.00% | -57.1% |
Q1 2018 | $28,830,000 | -19.6% | 1,283,046 | +7.7% | 0.01% | -22.2% |
Q4 2017 | $35,859,000 | -50.4% | 1,190,924 | -38.0% | 0.01% | -47.1% |
Q3 2017 | $72,338,000 | +35.9% | 1,920,278 | +0.6% | 0.02% | +21.4% |
Q2 2017 | $53,222,000 | +37.9% | 1,908,251 | +69.9% | 0.01% | +40.0% |
Q1 2017 | $38,605,000 | -16.8% | 1,122,899 | -30.2% | 0.01% | -28.6% |
Q4 2016 | $46,382,000 | +14.0% | 1,608,258 | +25.7% | 0.01% | +16.7% |
Q3 2016 | $40,691,000 | +255.8% | 1,279,191 | +263.0% | 0.01% | +200.0% |
Q2 2016 | $11,437,000 | -47.0% | 352,361 | -54.4% | 0.00% | -50.0% |
Q1 2016 | $21,593,000 | +171.8% | 772,268 | +246.7% | 0.01% | +166.7% |
Q4 2015 | $7,943,000 | +27.4% | 222,779 | +18.2% | 0.00% | 0.0% |
Q3 2015 | $6,234,000 | -44.5% | 188,487 | -29.7% | 0.00% | 0.0% |
Q2 2015 | $11,223,000 | +18.9% | 267,986 | -7.5% | 0.00% | -25.0% |
Q1 2015 | $9,441,000 | -79.5% | 289,682 | -80.0% | 0.00% | -71.4% |
Q4 2014 | $46,088,000 | -44.9% | 1,451,612 | -57.1% | 0.01% | -48.1% |
Q3 2014 | $83,694,000 | +4.4% | 3,380,225 | -4.8% | 0.03% | +8.0% |
Q2 2014 | $80,178,000 | -4.4% | 3,549,247 | +3.0% | 0.02% | -7.4% |
Q1 2014 | $83,857,000 | -13.1% | 3,446,680 | -10.7% | 0.03% | -15.6% |
Q4 2013 | $96,497,000 | -7.8% | 3,861,430 | +1.3% | 0.03% | -17.9% |
Q3 2013 | $104,674,000 | +28.8% | 3,810,477 | -14.9% | 0.04% | +25.8% |
Q2 2013 | $81,300,000 | +608.3% | 4,479,347 | +81.5% | 0.03% | +675.0% |
Q4 2012 | $11,478,000 | – | 2,468,299 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |